Spark Therapeutics Priced, Nasdaq: ONCE

Developing gene therapy treatments for orphan retinal dystrophies.

Industry: Health Care

Latest Trade: $72.68 0.00 (0.0%)

First Day Return: +117.4%

Return from IPO: +216.0%

Industry: Health Care

We are a leader in the field of gene therapy, seeking to transform the lives of patients suffering from debilitating genetic diseases by developing one-time, life-altering treatments. Our product candidates have the potential to provide long-lasting effects, dramatically and positively changing the lives of patients with conditions where no, or only palliative, therapies exist. Our initial focus is on treating orphan diseases, and we have demonstrated promising clinical outcomes with our first product candidate targeting rare blinding conditions, which has received both breakthrough therapy and orphan product designation and is in a fully enrolled, pivotal Phase 3 clinical trial with data expected in the second half of 2015. We also have built a pipeline of product candidates targeting additional blinding conditions, hematologic disorders and neurodegenerative diseases, including a second product candidate targeting another rare blinding condition, for which we have initiated enrollment in a clinical trial, and a collaboration with Pfizer for the development and commercialization of a gene therapy for the treatment of hemophilia B. Our platform technology is based on more than two decades of gene therapy research, development, manufacturing and clinical trials conducted at The Children’s Hospital of Philadelphia.
more less
IPO News for Spark Therapeutics
more
IPO Data
IPO File Date 12/30/2014
Offer Price $23.00
Price Range $19.00 - $21.00
Offer Shares (mm) 7.0
Deal Size ($mm) $161
IPO Data
IPO Date 01/29/2015
Offer Price $23.00
Price Range $19.00 - $21.00
Offer Shares (mm) 7.0
Deal Size ($mm) $161
Underwriters
more
Company Data
Headquarters Philadelphia, PA
Founded 2013
Employees 47
Website www.sparktx.com